December 9, 2009
CARVER, Mass.Decas Botanical Synergies (DBS) received notice from the Korean FDA approving a health claim for DBS PACran® and urinary health. The cranberry powder, standardized to proanthocyanidin (PAC) content, is the first product to receive a Korean health claim for urinary tract health, and is specific to PACran.
We are excited about the Korean FDA approval and the new opportunities for PACran it will offer, said Daniel Souza, DBS director of sales and marketing. We continue to invest in research to scientifically validate our products, which allows us to clearly distinguish ourselves. DBS continues to lead the global market with the most cost effective and efficacious cranberry products available.
According to DBS, the approval process for the PACran health claim took nearly two years to complete, and required DBS and its Korean partner, Monature, to submit a complete clinical dossier, including required safety data.
You May Also Like